Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McGill University

$354,884.00

Novel bivalent hybrid molecules with retinoic acid receptor agonistic and histone deacetylase inhibitory activity for cancer treatment

FY 2010-11

Summary
An effective way to combat cancer and other diseases is through combination therapy - the use of more than one therapeutic agent at a time in order to simultaneously target more than one biochemical process that may be responsible for a disease. In most cases, this is accomplished by administration of two separate drugs. In this research project, we attempt to combine two therapies in a single drug by making it bifunctional, able to interact with two separate biological targets. We have found that drugs which simultaneously target two particular biomolecules, a hormone receptor and an enzyme, histone deacetlase, that is important for regulation of expression of genes, are more effective against certain types of breast cancer. This project will optimize these drugs so that they may eventually enter clinical trials.
Program
Operating Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
226244
Name
Gleason James L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Novel bivalent hybrid molecules with retinoic acid receptor agonistic and histone deacetylase inhibitory activity for cancer treatment
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$354,884
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Breast Cancer; Histone Deacetylase Inhibitors; Hybrid Molecules; Retinoic Acid Receptor Agonists
Abstract
An effective way to combat cancer and other diseases is through combination therapy - the use of more than one therapeutic agent at a time in order to simultaneously target more than one biochemical process that may be responsible for a disease. In most cases, this is accomplished by administration of two separate drugs. In this research project, we attempt to combine two therapies in a single drug by making it bifunctional, able to interact with two separate biological targets. We have found that drugs which simultaneously target two particular biomolecules, a hormone receptor and an enzyme, histone deacetlase, that is important for regulation of expression of genes, are more effective against certain types of breast cancer. This project will optimize these drugs so that they may eventually enter clinical trials.
Competitiondate
201103
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gleason, James L; Mader, Sylvie N
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $354,884~ $0~
McGill University - $354,884 Grant (2010-11) | Canada Spends